The CURE study was designed to test the hypothesis that clopidogrel is superior to placebo in presenting cardiovascular death, MI or stroke in patients presenting to hospital with an acute coronary syndrome. (Unstable Angina or myocardial infarction without ST segment elevation).

The secondary objective was to evaluate the safety of clopidogrel in patients with an acute coronary syndrome who are receiving ASA therapy.